Pipeline· June 5, 2026 · 12 min read
Gedatolisib PDUFA preview: pan-PI3K/mTOR inhibitor targets HR+/HER2– breast cancer gap
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence
FDA breakthrough therapy designation, expedited development, evidence expectations, and launch-planning implications.